

Publikationen

2016

von Arnim U, Roehl FW, **Miehlke S**, Jechorek D, Reinhold D, Wex T, Malfertheiner P. Clinical symptom tool raise index of suspicion for eosinophilic oesophagitis in adults and drive earlier biopsy for definitive diagnosis. Aliment Pharmacol Ther 2016 Nov 29. doi: 10.1111/apt.13869.

Miehlke S, Loibl R, Meszaros S, Labenz J. Diagnostisches und therapeutisches Management der *Helicobacter pylori* Infektion: eine Umfrage unter niedergelassenen Gastroenterologen in Deutschland. Z Gastroenterol 2016;54:1130-1137.

Schulz C, Müller J, Sauter J, **Miehlke S**, Schmöcker C, Hartmann D, Malfertheiner P, Badiola C. [Superiority of a Split-dose Regimen of Sodium Picosulfate/Magnesium Citrate \(SPMC\) in Comparison to a Prior-day Schedule \(AM/PM\) for Colonoscopy Preparation. A Randomized Single-blinded Study.](#) J Gastrointestin Liver Dis 2016;25:295-302

Miehlke S, Hruz P, Vieth M, Bussmann C, von Arnim U, Baibouj M, Schlag C, Madisch A, Fibbe C, Wittenburg H, Allescher HD, Reinshagen M, Schubert S, Tack J, Müller M, Krummenerl P, Arts J, Mueller R, Dilger K, Greinwald R, Straumann A1. A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis. Gut 2016;65:390-9.

Münch A, Bohr J, **Miehlke S**, Benoni C, Olesen M, Öst A, Strandberg L, Hellström PM, Hertvig E, Armerding P, Stehlik J, Lindberg G, Björk Jan, Lapidus A, Löfberg R, Bonderup O, Avnström S, Rössle M, Dilger K, Mueller R, Greinwald R, Tysk C, Ström M on behalf of the BUC-63 investigators: Low-dose budesonide for maintenance of clinical remission in collagenous colitis: A randomized, placebo-controlled 12-month trial. Gut 2016;65:47-56

Teich N, Mohl W, Bokemeyer B, Bündgens B, Büning J, **Miehlke S**, Hüppe D, Maaser C, Klugmann T, Kruis W, Siegmund B, Helwig U, Weismüller J, Drabik A, Stallmach A; German IBD Study Group* Azathioprine-induced acute pancreatitis in patients with inflammatory bowel diseases - a prospective study on incidence and severity. J Crohns Colitis 2016;10:61-8.

von Arnim U, Wex T, Link A, Messerschmidt M, Venerito M, **Miehlke S**, Malfertheiner P. [Helicobacter pylori infection is associated with a reduced risk of developing eosinophilic oesophagitis.](#) Aliment Pharmacol Ther 2016;43:825-30.

Münch A, Tysk C, Bohr J, Madisch A, Bonderup OK, Mohrbacher R, Mueller R, Greinwald R, Ström M, **Miehlke S**. Smoking Status Influences Clinical Outcome in Collagenous Colitis. J Crohns Colitis 2016;10:449-54.

Fischbach W, Malfertheiner P, Lynen Jansen P, Bolten W, Bornschein J, Buderus S, Glocker E, Gross M, Hoffmann J, Koletzko S, Labenz J, Mayerle J, **Miehlke S**, Mössner J, Peitz U, Prinz C, Selgrad M, Suerbaum S, Venerito M, Vieth. S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit. Z Gastroenterol 2016;54:327-63.

Miehlke S. Mikroskopische Kolitis, Eosinophile Enterokolitis. In: Stange E: Chronisch-entzündliche Darmerkrankungen. Schattauer 2016: ISBN 978-3-7945-3081-6: 308-15.

2015

Miehlke S. Clinical Features of Eosinophilic Esophagitis in children and adults. Best Pract Res Clin Gastroenterol. 2015;29:739-48.

Miehlke S. Emerging treatments and future perspectives. In Strauman A. Eosinophilic Esophagitis. UNI-MED 2015; 1st Edition: 1002-107.

Westerlind H, Mellander MR, Bresso F, Munch A, Assadi G, Hübenthal M, Lieb W, Källberg H, Brynedal B, Padyukov L, Halfvarson J, Törkvist L, Andreasson A, Agreus L, Almer S, **Miehlke S**, Madisch A, Ohlsson B, Löfberg R, Hultcranz R, Franke A, D'Amato M. Dense genotyping of immune-related loci identifies H LA variants associated with increased risk of collagenous colitis. Gut. 2015 Nov 2. pii: gutjnl-2015-309934.

Porschen R, Buck A, Fischbach W, Gockel I, Görling U, Grenacher L, Hollerbach S, Hölscher A, Körber J, Messmann H, Meyer HJ, **Miehlke S**, Möhler M, Nöthlings U, Pech U, Schmidberger H, Schmidt M, Stahl M, Stuschke M, Thuss-Patience P, Trojan J, Vanhoefer U, Weimann A, Wenz F, Wullstein C. [S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus.](#) Z Gastroenterol 2015;53:1288-347.

Schlag C, **Miehlke S**, Heiseke A, Brockow K, Krug A, von Arnim U, Straumann A, Vieth M, Bussmann C, Mueller R, Greinwald R, Bajbouj M. [Peripheral blood eosinophils and other non-invasive biomarkers can monitor treatment response in eosinophilic oesophagitis.](#) Aliment Pharmacol Ther 2015;42:1122-30.

Langner C, Aust D, Ensari A, Villanacci V, Becheanu G, **Miehlke S**, Geboes K, Münch A on behalf of the Working Group of Digestive Diseases of the European Society of Pathology (ESP) and the European Microscopic Colitis Group (EMCG). Histology of Microscopic Colitis: Practical Approach for Pathologists. Histopathology 2015;66:613-26.

Miehlke S. Eosinophile Ösophagitis und Gastroenteritis - Kolibri oder Chamäleon? Klinikarzt 2015;44: 398–402.

Miehlke S. Mikroskopische Kolitis: Sehen wir nur die Spitze des Eisberges. JATROS 2015;9:39-41.

Gross M, Börsch G, Dormann A, Eckhardt AJ, Kiesslich R, **Miehlke S**, Labenz J. Colonoscopy in acute diverticulitis. Viszeralmedizin 2015;31:124-9.

2014

Miehlke S, Madisch A, Kupcinkas L, Petrauskas D, Heptner G, Böhm G, Dr. (5), Marks HJ, Neumeyer M, Nathan T, Fernández-Bañares F, Greinwald R, Mohrbacher R, Vieth M, Bonderup OK. Randomized, Placebo-controlled Multicenter Study of Budesonide and Mesalazine for Short-term Treatment of Collagenous Colitis. Gastroenterology 2014;146:1222-30.

Miehlke S. Clinical features of eosinophilic esophagitis. Dig Dis 2014;32:61-7.

Miehlke S. Eosinophilie Ösophagitis - neue Erkenntnisse und Entwicklungen. Dtsch Med Wochenschr 2014;139:272-4.

Koop H, Fuchs KH, Labenz J, Lynen Jansen P, Messmann H, **Miehlke S**, Schepp W, Wenzl T und die Mitarbeiter der Leitliniengruppe. S2k Guideline: Gastroesophageal Reflux Disease guided by the German Society of Gastroenterology. Z Gastroenterol 2014;52:1299-346.

Schmelz R, Bornhäuser M, Schetelig J, Kiani A, Platzbecker Uwe, Schwanebeck U, Grähler X, Uharek L, Aust D, Baretton G, Schwerdtfeger R, Hampe J, Greinwald R, Mueller R, Ehninger G, **Miehlke S**. Randomised, Double-blind, Placebo-controlled Trial of Oral Budesonide for Prophylaxis of Acute Intestinal Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation (PROGAST). BMC Gastroenterol 2014;14:197.

Madisch A, **Miehlke S**, Bartosch F, Bethke B, Stolte M. Microscopic colitis: Clinical presentation, treatment and outcome of 494 patients. Z Gastroenterol 2014;52:1062-1065

von Arnim U, **Miehlke S**, Madisch A, Vieth M, Straumann A, Malfertheiner P. [Eosinophilic esophagitis - update - pathogenesis, diagnosis and therapy](#). Z Gastroenterol 2014;52:296-305

2013

Miehlke S, Hansen JB, Madisch A, Schwarz F, Kuhlisch E, Morgner A, Teglbjaerg PS, Vieth M, Aust D, Bonderup OK. Risk factors for Symptom Relapse in Collagenous Colitis after withdrawal of Short-Term Budesonide Therapy. Inflamm Bowel Dis 2013;19:2763-7.

Miehlke S, Aust D, Madisch A. Microscopic colitis – new insights relevant to clinical practice. Z Gastroenterol 2013;51:1389-94.

Miehlke S. Mikroskopische Kolitis. Med Welt 2013;64:191-4.

Miehlke S, Alpan O, Schröder S, Straumann A. Induction of Eosinophilic Esophagitis by Sublingual Immunotherapy. Case Rep Gastroenterology 2013;7:363-6

Von Arnim U, **Miehlke S**. Eosinophile Ösophagitis – Wann daran denken, wie sicher, wie behandeln? Verdauungskrankheiten 2013;31:175-9.

Andresen V, Enck P, Frieling T, Kiesslich R, Labenz J, Layer P, **Miehlke S**, Mönnikes H, Pehl C, Schemann M, Storr M. Reizdarmsyndrom – Herausforderung in der täglichen Praxis. Thieme Praxis Report 2013;5:1-16.

Miehlke S. Ösophagus/Magen/Duodenum. In: Handbuch Gastroenterologie 2013. Herausgeber: C. Ell, W. Fischbach, P. Layer, H. Zirngibl. ISBN 978-3-86302-067-5 med publico GmbH.

2012

Miehlke S, Madisch A. Eosinophile Ösophagitis. In: Miehlke S: Topische Steroide in der Gastroenterologie, UNI-MED Bremen 2012, 1. Auflage, ISBN 978-3-8374-1361-8.

Madisch A, **Miehlke S**. Mikroskopische Kolitis. In: Miehlke S: Topische Steroide in der Gastroenterologie, UNI-MED Bremen 2012, 1. Auflage, ISBN 978-3-8374-1361-8.

Miehlke S. A novel treatment algorithm for microscopic colitis. In: Microscopic colitis – creating awareness for an underestimated disease. Editors: S. Miehlke, A. Münch, Falk Workshop Basel 2012, p61-65.

Miehlke S. Therapy. In: Microscopic Colitis. 1. Edition, UNI-MED 2012, Bremen (Editor: A. Tromm); ISBN 978-3-8374-1354-0.

Alpan O, **Miehlke S**, Straumann A. Oral immunotherapy for egg allergy in children. N Engl J Med 2012;367:1472

Münch A, Aust D, Bohr J, Bonderup O, Fernández Bañares F, Hjortswang H, Madisch A, Munck LK, Ström M, Tysk C, **Miehlke S**. Microscopic Colitis: current status, present and future challenges - Statements of the European Microscopic Colitis Group. J Crohn's Colitis 2012;6:932-45.

Miehlke S, Reinhold B, Schröder S. Successful treatment of Lichen planus esophagitis with topical Budesonide. Z Gastroenterol 2012;50:1104-7.

2011

Miehlke S, Aust D, Morgner A, Baretton G, Madisch A. Probe-based Confocal Laser Endomicroscopy in Double Balloon Enteroscopy. Z Gastroenterol 2011;49:1529-34.

Miehlke S, Krasz S, Schneider-Brachert W, Kulisch E, Berning B, Madisch A, Laaß M, Neumeyer M, Jebens C, Zekorn C, Knoth H, Jacobs E, Vieth M, Stolte M, Lehn N, Morgner A. Randomized Multicenter Study of Esomeprazole, Moxifloxacin and Amoxicillin for Second-Line or Rescue Treatment of *Helicobacter pylori* Infection. Helicobacter 2011;16:420-6.

Krasz S, **Miehlke S**, Berning M, Labenz J. Aktueller Stellenwert der Fluorochinolone in der Therapie der Helicobacter pylori Infektion. Z Gastroenterol 2011;49:989-96

Miehlke S, Löbe S, Madisch A, Kuhlisch E, Laass M, Grossmann D, Knoth H, Morgner A, Labenz J. [Intragastric acidity during administration of generic omeprazole or esomeprazole - a randomised, two-way crossover study including CYP2C19 genotyping.](#) Aliment Pharmacol Ther 2011;33:471-6.

Berning M, Krasz S, **Miehlke S**. Should quinolones come first in Helicobacter pylori therapy? Therap Adv Gastroenterol 2011;4:103-14

Miehlke S. Therapie. In: Mikroskopische Kolitis. 2. Auflage, UNI-MED Bremen (Hrsg. A. Tromm) 2011, (ISBN 978-3-8374-1333-5).

Madisch A, Hellmig S, Schreiber S, Bethke B, Stolte M, **Miehlke S**. [Allelic variation of the matrix metalloproteinase-9 gene is associated with collagenous colitis.](#) Inflamm Bowel Dis. 2011 Feb 8. doi: 10.1002/ibd.21640

Miehlke S. Differentialdiagnose Ösophagitis: Eosinophile Ösophagitis, Candida, Cytomegalievirus. Viszeralmedizin 2011;27:121-5.

2010

Pardi DS, **Miehlke S**. Microscopic colitis. In: Frontiers of Gastrointestinal Research, Editor: M.M. Lerch: Clinical Update on Inflammatory Disorders of the Gastrointestinal Tract, Editors: H. Tilg and J. Mayerle, Karger Verlag, Basel, 2010.

Bajbouj M, Vieth M, Rösch T, **Miehlke S**, Becker V, Anders M, Pohl H, Madisch A, Schuster T, Schmid RM, Meining A. Probe-based confocal laser endomicroscopy compared with standard four-quadrant biopsy for evaluation of neoplasia in Barrett's esophagus. *Endoscopy* 2010;42:435-440.

Wallace MB, Meining A, Canto MI, Fockens P, **Miehlke S**, Roesch T, Lightdale CJ, Pohl H, Carr-Locke D, Löhr M, Coron E, Filoche B, Giovannini M, Moreau J, Schmidt C, Kiesslich R. The safety of intravenous fluorescein for confocal laser endomicroscopy in the gastrointestinal tract. *Aliment Pharmacol Ther* 2010;31:548-52.

Distler M, Kersting S, Rueckert F, Dobrowolski F, **Miehlke S**, Grützmann R, Saeger HD. Palliative treatment of obstructive jaundice in patients with carcinoma of the pancreatic head or distal biliary tree: endoscopic stent placement vs. hepaticojejunostomy. *J Pankreas* 2010;11:1001-7.

Berning M, Krasz S, Labenz J, **Miehlke S**. Moderne Helicobacter pylori-Therapie in Zeiten zunehmender Antibiotikaresistenz. *Med Klinik* 2010;105:787-91

2009

Miehlke S, Madisch A, Karimi D, Wonschik S, Kuhlisch E, Beckmann R, Morgner A, Mueller R, Greinwald R, Seitz G, Baretton G, Stolte M. Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study. *Gastroenterology* 2009;136:2092-100.

Miehlke S. Ösophagus-Magen-Duodenum. In: Handbuch Gastroenterologie 2009. GastroUpdate. Reihe: **Handbuch Update-Seminar**, Med Update GmbH (Hrsg.) 2009, X, 380 S., Ringordner, ISBN: 978-3-642-00113-0.

Hofbauer LC, **Miehlke S**. [More on reports of esophageal cancer with oral bisphosphonate use.](#) *N Engl J Med* 2009;360:1790.

Bajbouj M, Becker V, Eckel F, **Miehlke S**, Pech O, Prinz C, Schmid RM, Meining A. [Argon plasma coagulation of cervical heterotopic gastric mucosa as an alternative treatment for globus sensations.](#) *Gastroenterology* 2009;137:440-4.

Fischbach W, Malfertheiner P, Hoffmann JC, Bolten W, Bornschein J, Götze O, Höhne W, Kist M, Koletzko S, Labenz J, Layer P, **Miehlke S**, Morgner A, Peitz U, Preiss JC, Prinz C, Rosien U, Schmidt WE, Schwarzer A, Suerbaum S, Timmer A, Treiber G, Vieth M. [S3-guideline "Helicobacter pylori and gastroduodenal ulcer disease"](#). *Z Gastroenterol* 2009;47:68-102.

Alberty J, Bisdas S, Issing PR, Kisch C, Madisch A, **Miehlke S**, Reiß G, Reiß M, Vogl TJ. Ösophagus. In: Facharztwissen HNO-Heilkunde. Herausgeber. M. Reiß, Springer Medizin Verlag Heidelberg 2009.

Fischbach W, Malfertheiner P, Hoffmann JC, Bolten W, Bornschein J, Götze O, Höhne W, Kist M, Koletzko S, Labenz J, Layer P, **Miehlke S**, Morgner A, Peitz U, Preiss J, Prinz C, Rosien U, Schmidt W, Schwarzer A, Suerbaum S, Timmer A, Treiber G, Vieth M; German society for hygiene and microbiology; German society for pediatric gastroenterology and nutrition e. V; German society for rheumatology. [S3-guideline "helicobacter pylori and gastroduodenal ulcer disease" of the German society for digestive and metabolic diseases](#)

[\(DGVS\) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e. V., German society for rheumatology, AWMF-registration-no. 021 / 001.](#) Z Gastroenterol 2009;47:1230-63.

2008

Miehlke S, Madisch A, Bethke B, Morgner A, Kuhlisch E, Henker C, Vogel G, Andersen M, Meier E, Baretton G, Stolte [Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial.](#) Gastroenterology 2008;135:1510-6.

Miehlke S, Schneider-Brachert W, Morgner A, Madisch A, Kirsch C, Haferland C, Bästlein E, Jebens C, Zekorn C, Knoth H, Stolte M, Lehn N. One-week once-daily triple therapy with esomeprazole, moxifloxacin and rifabutin is effective an effective rescue treatment for persistent *Helicobacter pylori* resistant to both metronidazole and clarithromycin. Helicobacter 2008;13:69-74.

Miehlke S. Therapie. In: Mikroskopische Kolitis. 1. Auflage, UNI-MED Bremen 2008 (Hrsg. A. Tromm); ISBN 978-3-8374-1044-0.

Madisch A, Morgner A, Stolte M, **Miehlke S**. [Investigational treatment options in microscopic colitis.](#) Expert Opin Investig Drugs 2008;17:1829-37.

Rugge M, Kim JG, Mahachai V, **Miehlke S**, Pennelli G, Russo VM, Perng CL, Chang FY, Tandon RK, Singal DK, Sung JJ, Valenzuela JE, Realdi G, Dore MP, Graham DY. [OLGA gastritis staging in young adults and country-specific gastric cancer risk.](#) Int J Surg Pathol 2008;16:150-4.

Halank M, Langner S, Kolditz M, **Miehlke S**, Höffken G. [Nocturnal oxygen desaturation is a frequent complication in portopulmonary hypertension.](#) Z Gastroenterol 2008;46:1260-5.

Madisch A, Schmolders J, Brückner S, Aust D, **Miehlke S**. [Less favorable clinical outcome after diagnostic and interventional double balloon enteroscopy in patients with suspected small-bowel bleeding?](#) Endoscopy 2008;40:731-4.

Grützmann R, Molnar B, Pilarsky C, Habermann JK, Schlag PM, Saeger HD, **Miehlke S**, Stolz T, Model F, Roblick UJ, Bruch HP, Koch R, Liebenberg V, Devos T, Song X, Day RH, Sledziewski AZ, Lofton-Day C [Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay.](#) PLoS One 2008;3:e3759.

2007

Miehlke S, Morgner A, Aust D, Madisch A, Vieth M, Baretton G. Combined use of Narrow band Imaging Magnification Endoscopy and Miniprobe Confocal laser Microscopy in Neoplastic Barrett's Esophagus. Endoscopy 2007, UCTN, 39: E1.

Miehlke S, Morgner A, Brückner S, Madisch A. APC treatment for small bowel angiodysplasias. In: Atlas of Double Ballon Enteroscopy; 2007:45-47. Editor: C.J.J. Mulder, Medconnect GmbH, Munich, Germany.

Miehlke S, Madisch A, Aust D, Morgner A, Laniado M, Saeger HD, Brückner S. Complicated localized small bowel Crohn's disease. In: Atlas of Double Ballon Enteroscopy; 2007:23-24. Editor: C.J.J. Mulder, Medconnect GmbH, Munich, Germany.

Miehlke S, Madisch A, Aust DE, Morgner A, Saeger HD, Brückner S. Resection of Peutz-Jeghers polyps. In: Atlas of Double Ballon Enteroscopy; 2007:75-77. Editor: C.J.J. Mulder, Medconnect GmbH, Munich, Germany.

Miehlke S, Brückner S, Aust D, Morgner A, Laniado M, Sinkwitz KD, Madisch A. Difficult differential diagnosis of small bowel Crohn's disease. In: Atlas of Double Ballon Enteroscopy; 2007:21-22. Editor: C.J.J. Mulder, Medconnect GmbH, Munich, Germany.

Miehlke S, Brückner S, Aust D, Morgner A, Madisch A. Retrieval of video capsules. In: Atlas of Double Ballon Enteroscopy; 2007:121-122. Editor: C.J.J. Mulder, Medconnect GmbH, Munich, Germany.

Madisch A, **Miehlke S**, Eichele O, Mrwa J, Bethke B, Kuhlisch E, Bästlein E, Wilhelms G, Morgner A, Wigglinghaus B, Stolte M. Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial. Int J Colorec Dis 2007, Sep 2; [Epub ahead of print].

Morgner A, **Miehlke S**, Labenz J. Esomeprazole: Prevention and Treatment of Non-Steroidal Anti-Inflammatory Drug (NSAID) - induced Symptoms and Ulcers. Exp Opin Pharmacother 2007;8:975-88.

Collet PH, **Miehlke S**. Blutstillung. In: Interventionelle Endoskopie – Lehrbuch und Atlas. Herausgeber: Kahl S, Kähler G, Dormann A. Elsevier GmbH, Urban & Fischer Verlag, München. 1. Auflage 2007.

Schmelz R, **Miehlke S**, Thiede C. Molekulare Pathogenese gastrointestinaler Lymphome. Verdauungskrankheiten 2007;6:248-56.

Morgner A, Stolte M, **Miehlke S**. Visualization of lymphoepithelial lesions in gastric MALT-type lymphoma by miniprobe confocal laser microscopy. Clin Gastroenterol Hepatol 2007, 5:e39.

Morgner A, Schmelz R, Thiede C, Stolte M, **Miehlke S**. Therapy of Gastric MALT lymphoma. World J Gastroenterol 2007;13: 242-251.

Schwarz U, Hanso H, Oertel R, **Miehlke S**, Kuhlisch E, Glaeser H, Hitzl M, Dresser GK, Kim RB, Kirch W. Induction of Intestinal P-glycoprotein by St. John's Wort Reduces the Oral Bioavailability of Talinolol. Clin Pharmacol Ther 2007; Mar 28; [Epub ahead of print].

Madisch A, Grützmann R, Aust D, Saeger HD, Ehninger G, **Miehlke S**. Acute bleeding in jejunal GIST. In: Atlas of Double Ballon Enteroscopy; 2007:96-97. Editor: C.J.J. Mulder, Medconnect GmbH, Munich, Germany.

2006

Miehlke S, Hansky K, Schneider-Brachert W, Kirsch C, Morgner A, Madisch A, Kuhlisch E, Bästlein E, Heptner G, Haferland C, Jacobs E, Bayerdörffer E, Lehn N, Stolte M. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of *Helicobacter pylori* resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther 2006;24:395-403.

Miehlke S, Menzel A, Brückner S, Aust D, Morgner A, Madisch A. Retrieval of two retained endoscopy capsules by retrograde double-balloon enteroscopy in a patient with a long history of small bowel disease. *Endoscopy* 2007; 39 Suppl 1:E157.

Madisch A, **Miehlke S**, Neuber F, Morgner A, Kuhlisch E, Seitz G, Rappel S, Lehn N, Bayerdörffer E, Stolte M. Healing of lymphocytic gastritis after *H. pylori* eradication therapy- a randomized, double-blind, placebo-controlled, multicenter trial. *Aliment Pharmacol Ther* 2006;23:473-9.

Madisch A, **Miehlke S**, Lindner M, Bethke B, Stolte M. Clinical course of collagenous colitis over a period of 10 years. *Z Gastroenterol* 2006;44:971-974.

Lucke K, **Miehlke S**, Jacobs E, Schuppler M. Population shift in colonic mucosa-associated microflora in ulcerative colitis. *J Med Microbiol* 2006;55:617-24.

Manner H, May A, **Miehlke S**, Dertinger S, Wigglinghaus B, Schimming W, Krämer W, Niemann G, Stolte M, Ell C. Ablation of nonneoplastic Barrett's mucosa using argon plasma coagulation with concomitant esomeprazole therapy (APBANEX): a prospective multicenter evaluation. *Am J Gastroenterol* 2006;101:1762-9.

Morgner A, Labenz J, **Miehlke S**. Effective Regimes for the treatment of *Helicobacter pylori* Infection. *Expert Opin Investig Drugs* 2006;15:995-1016.

Trautmann K, Stolte M, **Miehlke S**. *Helicobacter pylori* eradication in prevention of gastric cancer. *World J Gastroenterol* 2006;12:5101-7.

Kirsch C, Morgner A, **Miehlke S**. Relevance of cytochrome P450 polymorphism in the treatment of *Helicobacter pylori* infection and gastroesophageal reflux disease. *Current Pharmacogenomics* 2006;4:47-56.

Morgner-Miehlke A, Koop H, Blum AL, Hermans ML, **Miehlke S**, Labenz J. Symptom- versus Endoscopy-Based Diagnosis and Treatment of Gastroesophageal Reflux Disease (GERD). *Z Gastroenterol* 2006;44:399-410.

Madisch A, Hellmig S, Schreiber S, Bethke B, Stolte M, **Miehlke S**. *NOD2/CARD15* gene polymorphisms are not associated with collagenous colitis. *Int J Colorect Dis* 2006; Jun 28; [Epub ahead of print].

Rieger K, Lodenkemper C, Maul J, Fietz T, Wolff D, Terpe H, Steiner B, Berg E, **Miehlke S**, Bornhauser M, Schneider T, Zeitz M, Stein H, Thiel E, Duchmann R, Uharek L. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. *Blood* 2006;107:1717-23.

2005

Miehlke S, Madisch A, Voss C, Morgner A, Heymer P, Kuhlisch E, Bethke B, Stolte M. Long-term follow-up of collagenous colitis after induction of clinical remission with budesonide. *Aliment Pharmacol Ther* 2005;22:1115-9.

Miehlke S, Madisch A, Bethke B, Stolte M. Time to remission with budesonide in collagenous colitis. *Aliment Pharmacol Ther* 2005;21:1507-8.

Miehlke S, Madisch A, Kirsch C, Lindner F, Kuhlisch E, Laass M, Knoth H, Morgner A, Labenz J. Intra-gastric acidity during treatment with esomeprazole 40 mg twice daily and

pantoprazole 40 mg twice daily – a randomized, two-way crossover study. *Aliment Pharmacol Ther* 2005;21:963-7.

Madisch A, **Miehlke S**, Bayerdörffer E, Wiedemann B, Antos D, Sievert A, Vieth M, Stolte M, Schulz H. Long-term follow-up after complete ablation of Barrett's esophagus with argon plasma coagulation. *World J Gastroenterol* 2005;11:1182-6.

Madisch A, **Miehlke S**, Labenz J. Management of functional dyspepsia: Unsolved problems and new perspectives. *World J Gastroenterol* 2005;11:6577-81.

Halank M, **Miehlke S**, Kolditz M, Hoeffken G. Portopulmonale Hypertonie. *Z Gastroenterol* 2005;43:677-85.

Morgner-Miehlke A, Petersen, KU, **Miehlke S**, Labenz J. Review of Esomeprazole: potent acid suppression in the treatment of acid related disorders. *Exp Rev Clin Immunol* 2005,1: 513-529.

Schwarz UI, Seemann D, Oertel R, **Miehlke S**, Kuhlisch E, Fromm MF, Kim RB, Bailey DG, Kirch W. Grapefruit Juice Ingestion significantly reduces Talinolol Bioavailability. *Clin Pharmacol Ther* 2005;77:291-301.

Trautmann K, Steudel C, Grossmann D, Aust D, Ehninger G, **Miehlke S**, Thiede C. Expression profiling from gastric cancer samples by oligonucleotide micro array analysis reveals low degree of intra-tumor variability. *World J Gastroenterol* 2005;11:5993-6.

Madisch A, Heymer P, Voss C, Wigglinghaus B, Bästlein E, Bayerdörffer E, Meier E, Schimming W, Bethke B, Stolte M, **Miehlke S**. Oral Budesonide therapy improves quality of life in patients with collagenous colitis. *Int J Colorect Dis* 2005;20:312-6.

2004

Miehlke S, Morgner A, Ehninger G. Gastric MALT lymphoma and gastrointestinal stromal tumors. *Schweiz Rundsch Med Praxis* 2004;93:2143-50.

Krah A, **Miehlke S**, Pleissner KP, Zimny-Arndt U, Kirsch C, Lehn N, Meyer TF, Jungblut PR, Aebischer T. Identification of candidate antigens for serologic detection of *Helicobacter pylori* infected patients with gastric carcinoma. *Int J Cancer* 2004;108:456-63.

Morgner A, **Miehlke S**. Komplikationen der peptischen Ulkuskrankheit: Diagnostik und Therapie der akuten nicht-varikösen oberen Gastrointestinalblutung. *Medizin* 200 plus 1/2004.

Madisch A, **Miehlke S**, Plein K, Hollerbach S. Diagnosesicherung und Behandlungsmöglichkeiten bei funktioneller Dyspepsie. *Der Mediziner*, Ausgabe 3/2004.

Madisch A, **Miehlke S**, Plein K, Hollerbach S. Diagnosesicherung und Behandlungsmöglichkeiten bei funktioneller Dyspepsie. *Facharzt* 2/2004.

Backert S, Schwarz T, **Miehlke S**, Kirsch C, Sommer C, Kwok T, Gerhard M, Goebel U, Lehn N, König W, Meyer TF. Functional analysis of the cag pathogenicity island in *Helicobacter pylori* isolates from patients with gastritis, peptic ulcer and gastric cancer: *Infect Immun* 2004;72:1043-1056.

Jüttner S, Vieth M, **Miehlke S**, Schneider-Brachert W, Kirsch C, Pfeuffer T, Lehn N, Stolte M. Reliable detection of macrolid-resistant *Helicobacter pylori* via fluorescence in situ hybridisation in formalin-fixed tissue. *Mod Pathol* 2004;17:684-9.

Kirsch C, Madisch A, Piehler P, Bayerdörffer E, Stolte M, **Miehlke S**. *Helicobacter pylori* in gastritic corpus 20 years after partial gastric resection. *World J Gastroenterol* 2004;10:2560-2.

2003

Miehlke S, Kirsch C, Schneider-Brachert W, Haferland C, Neumeyer M, Bästlein E, Vieth M, Stolte M, Lehn N, Bayerdörffer E. A prospective, randomized study of quadruple therapy and high-dose omeprazole/amoxicillin therapy for treatment of *Helicobacter pylori* resistant to both metronidazole and clarithromycin. *Helicobacter* 2003;8:310-319.

Miehlke S, Schneider-Brachert W, Bästlein E, Ebert S, Kirsch C, Haferland C, Buchner M, Neumeyer M, Vieth M, Stolte M, Lehn N, Bayerdörffer E. One-week triple therapy with esomeprazole, clarithromycin and metronidazole is effective in eradicating *Helicobacter pylori* in the absence of antimicrobial resistance. *Aliment Pharmacol Ther* 2003;18:799-804.

Miehlke S. *Helicobacter pylori* and gastric carcinogenesis. In: Disease Progression and Carcinogenesis in the Gastrointestinal Tract. Eds. P. Galle et al. Kluwer Academic Publishers, Dordrecht, Boston, London, November 2003.

Madisch A, Kulich KR, Malfertheiner P, Ziegler K, Bayerdörffer E, **Miehlke S**, Labenz J, Carlsson J, Wiklund IK. Burden of Illness in Patients with Reflux Disease – Evidence from a Recent Comparative Methodological Study in Germany. *Z Gastroenterol* 2003;41:1137-1143.

Kulich KR, Malfertheiner P, Madisch A, Labenz J, Bayerdorffer E, **Miehlke S**, Carlsson J, Wiklund IK. Psychometric validation of the German translation of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in patients with reflux disease. *Health and Quality of Life Outcomes* 2003,1:62.

Smith S, Lück PC, Bayerdörffer E, **Miehlke S**. Genotyping of Nigerian *Helicobacter pylori* isolates by pulsed-field gel electrophoresis. *J Med Microbiol* 2003;52:931.

Smith SI, Chibututu C, Anomneze E, Atimomo C, Atoyebi O, Ndububa D, Agbakwuru A, Bayerdörffer E, **Miehlke S**. Molecular typing of Nigerian *Helicobacter pylori* isolates by glmM restriction fragment length polymorphism. *Br J Biomed Sci* 2003;60:170-2.

2002

Miehlke S, Heymer P, Bethke B, Bästlein E, Meier E, Bartram HP, Wilhelms G, Lehn N, Dorta G, DeLarive J, Tromm A, Bayerdörffer E, Stolte M. Budenoside treatment for collagenous colitis – a randomized, double-blind, placebo-controlled, multicenter trial. *Gastroenterology* 2002;123:978-84.

Miehlke S, Yu J, Ebert M, Szokodi D, Vieth M, Kuhlisch E, Buchcik R, Schimming W, Wehrmann U, Malfertheiner P, Stolte M, Ehninger G, Bayerdörffer E. Expression of G1 phase cyclins in human gastric cancer, intestinal metaplasia, and in the gastric mucosa of first degree relatives. *Dig Dis Sci* 2002;47:1248-56.

Smith SI, **Miehlke S**, Oyedeji KS, Arigbabu AA, Coker AO. Fingerprinting of Nigerian *Helicobacter pylori* Isolates by plasmid profile and PCR. *J Basic Microbiol* 2002;1:45-53.

Meining A, Wick M, **Miehlke S**, Bayerdörffer E, Stolte M, Sackmann M, Ochsenkühn T. The presence of immunoglobulins in the gastric juice of patients infected with *Helicobacter pylori* is related to a reduced secretion of acid. *Helicobacter* 2002;7:67-70.

Stolte M, Meining A, **Miehlke S**, Bayerdörffer E. Progress in understanding of *H. pylori* infection and gastritis. In: *Helicobacter pylori – Basic Mechanisms to Clinical Cure 2002*, Eds. R.H. Hunt, G.N.J. Tytgat, Kluwer Academic Publishers, Dordrecht, Boston, London, November 2002.

Smith SI, Kirsch C, Oyedeji KS, Arigbabu AO, Coker AO, Bayerdörffer E, **Miehlke S**. Prevalence of *Helicobacter pylori vacA*, *cagA*, and *iceA* genotypes in Nigerian patients with duodenal ulcer disease. *J Med Microbiol* 2002 ;51:851-4.

Smith S, Cantet F, Angelini F, Marais A, Megraud F, Bayerdoffer E, **Miehlke S**. Discriminatory power of RAPD, PCR-RFLP and southern blot analyses of ureCD or ureA gene probes on *Helicobacter pylori* isolates. *Z Naturforsch* 2002;57:516-21.

2001

Miehlke S, Yu J, Schuppler M, Frings C, Kirsch C, Negraszus N, Morgner A, Stolte M, Ehninger G, Bayerdörffer E. *Helicobacter pylori vacA*, *iceA*, and *cagA* status, and pattern of gastritis in patients with malignant and benign gastroduodenal disease. *Am J Gastroenterol* 2001;96:1008-13.

Miehlke S, Kirsch C, Dragosics B, Gschwantler M, Oberhuber G, Antos D, Dite P, Läuter J, Labenz J, Leodolter A, Malfertheiner P, Neubauer A, Ehninger G, Stolte M, Bayerdörffer. *Helicobacter pylori* and Gastric Cancer: Current Status of the Austrian-Czech-German Gastric Cancer Prevention Trial (PRISMA-Study). *World J Gastroenterol* 2001;7:243-7.

Miehlke S, Bayerdörffer E, Graham DY. Treatment of *H. pylori* infection. *Seminars in Gastrointestinal Diseases* 2001;12:167-79.

Miehlke S, Bayerdörffer E, Ehninger G, Stolte M. Präkanzeröse Risikomarker der *Helicobacter pylori*-Gastritis. *Pathologe* 2001,22:31-6.

Morgner A, **Miehlke S**, Fischbach WK, Schmitt W, Müller-Hermelink HK, Greiner A, Thiede C, Schetelig J, Neubauer A, Stolte M, Ehninger G, Bayerdörffer E. Complete remission of primary high-grade B-cell gastric lymphoma after cure of *Helicobacter pylori* infection. *J Clin Oncol* 2001;19:2041-8.

Morgner A, **Miehlke S**, Bayerdörffer E, Neubauer A, Thiede C, Klann H, Hierlmeier FX, Ehninger G, Stolte M. Development of early gastric cancer 4 years after complete remission of *Helicobacter pylori*-assoiated gastric low-grade B-cell MALT lymphoma. *World J Gastroenterol* 2001;248-53.

Meining A, Morgner A, **Miehlke S**, Bayerdörffer E, Stolte M. Atrophy-metaplasia-dysplasia-carcinoma sequence in the stomach: a reality or merely an hypothesis? *Best Pract Res Clin Gastroenterol* 2001;15:983-98.

2000

Miehlke S, Kirsch C, Agha-Amiri K, Günther T, Lehn N, Malfertheiner P, Stolte M, Ehninger G, Bayerdörffer E. The *Helicobacter pylori vacA s1;m1* genotype and *cagA* is associated with gastric carcinoma in Germany. *Int J Cancer* 2000; 87:322-7.

Schulz H, **Miehlke S**, Antos D, Vieth M, Schentke KU, Stolte M, Bayerdörffer E. Ablation of Barrett's epithelium by endoscopic argon plasma ablation combined with high-dose omeprazole treatment. *Gastrointest Endosc* 2000;51:659-63.

Yu J, **Miehlke S**, Ebert MP, Hoffmann J, Breidert M, Alpen B, Starzynska T, Stolte M, Malfertheiner P, Bayerdörffer E. Frequency of TPR-MET rearrangement in patients with gastric carcinoma and in first-degree relatives. *Cancer* 2000;88:1801-6.

Ebert M, Yu J, **Miehlke S**, Lendeckel U, Neubauer A, Stolte M, Bayerdörffer E, Malfertheiner P. Expression of transforming growth factor beta-1 in gastric cancer and in the gastric mucosa of first-degree relatives of patients with gastric cancer. *Brit J Cancer* 2000;82:1795-800.

Yu J, Ebert MP, **Miehlke S**, Rost H, Lendeckel U, Leodolter A, Stolte M, Bayerdorffer E, Malfertheiner P. Alpha-catenin expression is decreased in human gastric cancers and in the gastric mucosa of first degree relatives. *Gut* 2000;46:639-44.

Ebert MP, Günther T, Hoffmann J, Yu J, **Miehlke S**, Schulz HU, Roessner A, Korc M, Malfertheiner P. Expression of metallothionein II in intestinal metaplasia, dysplasia, and gastric cancer. *Cancer Res* 2000;60:1995-2001.

1999

Miehlke S, Genta RM, Graham DY, Go MF. Molecular relationships of *Helicobacter pylori* strains in a family with gastroduodenal disease. *Am J Gastroenterol* 1999;94:364-368.

Miehlke S, Thomas R, Guitierrez O, Graham DY, Go MF. DNA fingerprinting of single colonies of *Helicobacter pylori* from gastric cancer patients suggests infection with a single predominant strain. *J Clin Microbiol* 1999;137:245-247.

Miehlke S, Bayerdörffer E, Malfertheiner P. Treatment of *Helicobacter pylori* reinfection. In: Scarpignato C, Bianchi Porro G (eds.): *Clinical pharmacology & therapy of Helicobacter pylori* infection. *Prog Basic Clin Pharmacol*. Basel. Karger 1999;11:346-52.

Breidert M, **Miehlke S**, Orban Z, Glasow A, Stolte M, Ehninger G, Bayerdörffer E, Nettesheim O, Halm U, Haidan A, Bornstein SR. Leptin and its receptor in normal human gastric mucosa and in *Helicobacter pylori* gastritis. *Scand J Gastroenterol* 1999;34:954-961.

Lucke K, **Miehlke S**, Schuppler M. Comparative 16S rRNA analysis of the colorectal mucosa-associated bacterial flora in patients with ulcerative colitis. *Hygiene Mikrobiologie* 1999;3:24-5.

Bayerdörffer E, **Miehlke S**, Labenz J, Dragosics B, Läuter J, Neubauer A, Malfertheiner P, Stolte M. Magenkarzinomprophylaxe durch *Helicobacter pylori* -Eradikation? - Einladung zur Teilnahme an der PRISMA-Studie. *Z Gastroenterol* 1999;37:XXI-XXV.

Bayerdörffer E, **Miehlke S**, Labenz J, Stolte M, Malfertheiner P. Prävention des Magenkarzinoms. Ist eine Eradikation von *Helicobacter pylori* sinnvoll? *Deutsches Ärzteblatt* 1999;96:A-1786-1788.

Breidert M, **Miehlke S**, Gillespie J, Ehninger G, Bornstein SR. Die Laser Capture Mikrodisektion: moderne Analyse molekulargenetischer Alterationen. *Onkologe* 1999;5:170-2.

Gerhard M, Lehn N, Neumayer N, Boren T, Rad R, Schepp W, **Miehlke S**, Classen M, Prinz C. Clinical relevance of the *Helicobacter pylori* gene for blood group antigen binding adhesin. *Proc Natl Acad Sci* 1999;96:12778-83.

1998

Miehlke S, Go MF, Kim JG, Graham DY, Figura N. Serologic detection of *Helicobacter pylori* infection with *cagA*⁺ strains in duodenal ulcer, gastric cancer, and asymptomatic gastritis. *J Gastroenterol* 1998;33:18-21.

Miehlke S, Hackelsberger, Meining A, Hatz R, Lehn N, Malfertheiner P, Stolte M, Bayerdörffer E. Severe expression of corpus gastritis is characteristic in gastric cancer patients infected with *Helicobacter pylori*. *Brit J Cancer* 1998;78:263-266.

Miehlke S, Meining A, Lehn N, Höchter W, Weingart J, Simon T, Krämer W, Klann H, Bolle KH, Sommer A, Stolte M, Bayerdörffer E. Comparison of omeprazole, metronidazole and clarithromycin with omeprazole/amoxicillin dual therapy for the cure of *Helicobacter pylori* infection. *Digestion* 1998;59:646-650.

Miehlke S, Meining A, Morgner A, Bayerdörffer E, Lehn N, Stolte M, Graham DY, Go MF. Frequency of *vacA* genotypes and cytotoxin activity in *Helicobacter pylori* associated with gastric MALT-lymphoma. *J Clin Microbiol* 1998; 36:2369-2370.

Miehlke S, Bayerdörffer E, Malfertheiner P. *Helicobacter pylori* Infektion und die Entwicklung von Magenneoplasien. *Verdauungskrankheiten* 1998;16:77-83.

Stolte M, Bayerdörffer E, **Miehlke S**, Meining A, Dragosics B, Oberhuber G, Malfertheiner P. *Helicobacter pylori* -Eradikation zur Prophylaxe des Magenkarzinoms - Einladung zur deutsch-österreichischen PRISMA-Studie. *Leber Magen Darm* 1998;28:128-135.

Meining A, Stolte M, Müller P, **Miehlke S**, Lehn N, Hölzel D, Bayerdörffer E. Gastric carcinoma risk index in patients infected with *Helicobacter pylori*. *Virchows Arch* 1998;432:311-314.

Schulz V, Hackelsberger A, Günther T, **Miehlke S**, Roessner A, Malfertheiner P. Differing patterns of *Helicobacter pylori* gastritis in patients with duodenal, prepyloric and gastric ulcer diseases. *Scand J Gastroenterol* 1998;33:137-142.

Stolte M, Bayerdörffer E, Meining A, **Miehlke S**, Malfertheiner P. *Helicobacter pylori* und Magenkarzinom - Ist eine präventive Interventionsstudie sinnvoll? *Pathologie* 1998; 19:330-334.

1997

Miehlke S, Mannes GA, Lehn N, Bayerdörffer E, Hele C, Stolte M. An increasing dose of omeprazole combined with amoxicillin cures *Helicobacter pylori* infection more effectively. *Aliment Pharmacol Ther* 1997;11:323-329.

Miehlke S, Hackelsberger A, Meining A, v. Arnim U, Müller P, Ochsenkühn T, Lehn N, Malfertheiner P, Stolte M, Bayerdörffer E. Histological diagnosis of *Helicobacter pylori* gastritis predicts is predictive of high risk of gastric carcinoma. *Int J Cancer* 1997, 73:837-39.

Miehlke S, Graham DY. Antimicrobial therapy of peptic ulcers. *International Journal of Antimicrobial Agents* 1997;8:171-78.

Miehlke S, Bayerdörffer E, Meining A, Stolte M, Malfertheiner P. Identifying persons at risk for gastric cancer? *Helicobacter* 1997;2:S61-S66.

Bayerdörffer E, **Miehlke S**, Neubauer A, Stolte M. Gastric MALT lymphoma and *Helicobacter pylori* Infection. *Aliment Pharmacol Ther* 1997;11:89-94.

Malfertheiner P, **Miehlke S**. *Helicobacter pylori* infection in ulcer pathogenesis. *Digestion* 1997;58:17-20.

Meining A, Stolte M, Hatz R, Lehn N, **Miehlke S**, Morgner A, Bayerdörffer E. Differing degree and distribution of gastritis in *Helicobacter pylori* associated diseases. *Virchows Arch* 1997, 431:11-15.

1996

Miehlke S, Bayerdörffer E, Lehn N, Mannes GA, Sommer A, Höchter W, Weingart J, Heldwein W, Hatz R, Stolte M. Severity of *Helicobacter pylori* gastritis predicts duodenal ulcer recurrence. *Scand J Gastroenterol* 1996;31:856-862.

Miehlke S, Kibler K, Kim JG, Figura N, Small SM, Graham DY, Go MF. Allelic variation in *Helicobacter pylori cagA* gene from Korea compared to the United States. *Am J Gastroenterol* 1996;91:1322-1325.

Miehlke S, Osato M, Reddy R, Wood P, Conneely O, Graham DY. Direct antibacterial activity of recombinant human lactoferrin against *Helicobacter pylori*. *J Clin Microbiol* 1996;34:2593-94.

Miehlke S, Bayerdörffer E, Lehn N, Meining A, Bästlein E, Mannes GA, Stolte M. *Helicobacter pylori* reinfection is rare in peptic ulcer patients cured by antimicrobial therapy. *Eur J Gastroenterol* 1996; 8:1161-63.

Miehlke S, Malfertheiner P. Ulkushpathogenese: Die Rolle von *Helicobacter pylori*. *Zeitschrift für Allgemeinmedizin* 1996;72: 668-671.

Bayerdörffer E, **Miehlke S**, Lehn N, Mannes GA, Höchter W, Weingart J, Klann H, Sommer A, Heldwein W, Hatz R, Simon T, Bolle KH, Bästlein E, Meining A, Ruckdeschel G, Stolte M. Cure of gastric ulcer disease after cure of *Helicobacter pylori* infection. *Eur J Gastroenterol* 1996;8:343-349.

1995

Miehlke S, Bayerdörffer E, Lehn N, Mannes GA, Sommer A, Höchter W, Weingart J, Bästlein E, Hatz R, Ruckdeschel G, Dirschedl P, Stolte M. Two-year follow-up of duodenal ulcer patients after treatment with omeprazole and amoxicillin. *Digestion* 1995;56:187-193.

Miehlke S, Bayerdörffer E, Lehn N, Mannes GA, Höchter W, Weingart J, Sommer A, Heldwein W, Ruckdeschel G, Köpke W, Stolte M. Recurrence of duodenal ulcers during a

five-year follow-up after cure of *Helicobacter pylori* infection. Eur J Gastro Hepatol 1995;7:975-978.

Bayerdörffer E, **Miehlke S**, Lehn N, Mannes GA, Sommer A, Höchter W, Heldwein W, Weingart J, Klann H, Simon T, Schmitt W, Bästlein E, Eimiller A, Hatz R, Dirschedl P, Stolte M. Double blind trial of omeprazole and amoxicillin to cure *Helicobacter pylori* infection in patients with duodenal ulcers. Gastroenterology 1995;108:1412-1417.

Bayerdörffer E, **Miehlke S**, Mannes GA. Indikationen und Therapieempfehlungen zur *Helicobacter pylori*-Eradikation. Der Bayerische Internist 1995;15:64-70.

1994

Bayerdörffer E, **Miehlke S**, Mannes GA. *Helicobacter pylori*-Eradikationstherapie mit Omeprazol und Amoxicillin: Heutiger Stand. Leber Magen Darm 1994;24:228-232.

Bayerdörffer E, **Miehlke S**, Mannes GA. Eradikationstherapie beim Ulcus duodeni: Ergebnisse, Indikation und Therapieempfehlungen. Gastro-Liga Report 1994;3/4:15-19.

1993

Bayerdörffer E, **Miehlke S**, Lehn N, Mannes GA, Sommer A, Höchter W, Hatz R, Stolte M. Chronic type B-gastritis as an important denominator of peptic ulcer healing. Eur J Gastroenterol Hepatol 1993;5: 99-105.